Close Menu

NEW YORK (GenomeWeb News) – Bayer Healthcare and the Broad Institute today announced a strategic alliance to jointly discover and develop therapeutic agents that target cancer genome alterations.

As part of the five-year deal, the partners will share their expertise on identifying and characterizing genes that are associated with cancer. They will also apply their screening platforms on compounds found in their libraries in order to identify those with potential as therapeutic agents.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.